In clinical trials of complicated intra-abdominal infections, assessment of adequacy of the initial surgical approach to the management of the infection is of considerable importance in determining outcome. Antibiotic therapy would not be expected to adequately treat the infection if the surgical procedure was inadequate with respect to source control. Inclusion of such cases in an efficacy analysis of a particular therapeutic antibiotic may confound the results. We analyzed the source control review process used in double-blind clinical trials of antibiotics in complicated intra-abdominal infections identified through systematic review. We searched MEDLINE (PubMed) and ClinicalTrials.gov databases to identify relevant articles reporting results from double-blind clinical trials that used a source control review process. Eight prospective, randomized, doubleblind, multicenter, clinical trials of 5 anti-infective agents in complicated intra-abdominal infections used a source control review process. We provide recommendations for an independent, adjudicated source control review process applicable to future clinical trials.
Randomized clinical trials are routinely used to assess various therapeutic interventions for complicated intraabdominal infections (cIAIs). As compared with other infections that are studied in randomized trials, cIAIs are further defined by a requirement for some form of intervention, either operative or percutaneous [1] . At a minimum, intervention is needed to drain fluid collections and decrease the bacterial burden. Additional elements of source control that may be required in the individual case include management of the underlying pathological process (eg, bowel perforation), debridement of devitalized tissue, drainage, and appropriate wound management.
It is widely accepted that systemic antibiotic therapy improves outcome results. Under certain circumstances, the procedure performed may not be adequate to control the source of infection. This may occur due to incomplete diagnosis, anatomic conditions not allowing the procedure of choice to be performed, hemodynamic instability in the operating room, judgment error, or technical error.
Because the clinical outcome is dependent on both the procedure and the effect of the antimicrobial agent, inadequate procedures diminish the likelihood of clinical cure [2, 3] . Inclusion of such cases in an efficacy analysis of a particular antimicrobial agent under study may confound the results and distort the assessment of the effect of the antimicrobial agent.
Given the wide variations in patient comorbidities, pre-operative diagnostic studies, anatomy, and pathology encountered, firm a priori decision rules for source control applicable to individual patients for inclusion in clinical trials become difficult and may introduce selection bias. A less biased approach to the assessment of adequacy of source control is a blinded consensus review process [4] .
We performed a systematic review and identified 8 prospective, randomized, double-blind clinical trials of anti-infective agents in cIAI that used some form of source control review. On the basis of this review and our experiences, we then provide recommendations for an independent, adjudicated source control review process applicable to future clinical trials.
METHODS

Literature Search
We searched MEDLINE (PubMed) and ClinicalTrials.gov databases to identify relevant articles, using the keywords [antibiotic name] AND intra-abdominal NOT urinary NOT pneumonia with the following limits: humans, clinical trial, randomized controlled trial, English, and all adults ≥19 years. The antibiotic names used were metronidazole, tinidazole, clindamycin, imipenem, ertapenem, biapenem, doripenem, piperacillin (returns all piperacillin and tazobactam studies), cefazolin, cefamandole, cephaloridine, cefoxitin, cefmetazole, cefotaxime, ceftriaxone, cefepime, ceftazidime, ceftizoxime, cefoperazone, moxalactam, aztreonam, ciprofloxacin, moxifloxacin, levofloxacin, trovafloxacin, gentamicin, tobramycin, amikacin, netilmicin, tigecycline, minocycline, tetracycline, doxycycline, ampicillin, amoxicillin, ticarcillin, mezlocillin, and carbenicillin.
Data Extraction
This search returned in aggregate 372 references; after excluding duplicates, 146 remained. A title review excluded an additional 55 studies, most of which were prophylaxis studies. The remaining 91 studies were screened by abstract or full text review, as needed. We also reviewed all intra-abdominal studies reported in the ClinicalTrials.gov database. We did not identify additional studies that have been completed. Eight prospective, randomized, double-blind, multicenter, clinical trials of 5 antiinfective agents in cIAIs used a source control review process [5] [6] [7] [8] [9] [10] [11] [12] .
Clinical Assessments and Definitions in Trials Using Source Control Review
The primary or coprimary analysis population for clinical assessments included treated patients who underwent an operative or percutaneous procedure that identified an intraabdominal infectious process and had cultures from the abdomen or blood cultures positive for pathogenic bacteria. This analysis population was referred to as the efficacy valid population in the ciprofloxacin trial [5] , the evaluable population in the clinafloxacin trial [6] , the microbiologically evaluable per-protocol population in the ertapenem trials [7, 8] , and the microbiologic modified intent-to-treat population in the later tigecycline and doripenem trials [9] [10] [11] [12] .
All patients who received study therapy were assigned an outcome of success, failure, or indeterminate by the principal investigator. Failure was generally defined in the trials as death related to abdominal infection at any time point, persistent or recurrent infection within the abdomen, or postsurgical wound infection. Patients who received post-study treatment with additional antibiotics for undocumented intra-abdominal infection also were considered failures.
Patients who were considered to have inadequate initial interventions after committee review were excluded from the evaluable population for efficacy analyses. While there was some similarity to overall approach, there was considerable variation in definition of analysis populations and evaluability.
RESULTS
Ciprofloxacin/metronidazole
This trial compared ciprofloxacin/metronidazole with imipenem/cilastatin [5] . For clinical failures, the principal investigator determined the adequacy of intervention by review of the case report form and supplemental information. Cases considered to possibly have inadequate intervention were reviewed by a blinded 8-member review committee, which made the final determination on adequacy of source control.
Of the 55 cases reviewed for source control, 6 (11%) were determined to have had inadequate initial operations (Table 1) .
Clinafloxacin
This trial compared clinafloxacin with imipenem/cilastatin [6] . All case report forms were initially reviewed by the principal investigator to determine the possibility of inadequate intervention. For surgical procedures, adequacy was defined by drainage of all purulent collections identified on preoperative radiographic examination and by removal of the source of infection. For percutaneous procedures, adequacy was defined by the absence of subsequent drainage procedures not planned at the time of the initial computed tomography or ultrasound image. Cases not meeting these criteria for adequacy were referred to an expert panel of surgeons experienced in the surgical and antimicrobial management of patients with cIAI and in analysis of clinical trials data.
After expert panel review, 9 of 59 (15%) cases reviewed for source control were considered to have had inadequate initial interventions (Table 1) .
Ertapenem
The first trial compared ertapenem with piperacillin/tazobactam [7] . A prospective, expert panel review was conducted to assess the adequacy of surgical source control under blinded conditions in patients who were clinical failures as a component of evaluability. The committee included 7 surgeons and 1 interventional radiologist. The committee reviewed all cases scored as a failure by the investigator and all cases in which an unplanned second procedure was performed and when these cases were considered cured by the investigator. Data for source control review included case report forms, operative notes, and narrative summaries of the cases.
For operative procedures, adequacy was defined as control of the underlying pathologic process by resection, closure, or drainage, and drainage of existing purulent collections. For percutaneous procedures, adequacy was determined by review of imaging studies by an experienced interventional radiologist and included adequate drainage of all initial collections. In the first step, 3 reviewers independently assessed the adequacy of the intervention for each case. If complete agreement was reached among the 3 reviewers that the initial procedure was adequate, or that in the case of a second procedure there was no evidence of clinical failure, then source control was considered adequate. If there was any discordance, the case went to the full panel for discussion and majority decision.
The expert panel reviewed 145 of 633 (23%) randomized patients (Table 1 ). Of these, 22 (9 ertapenem and 13 piperacillin/ tazobactam) were judged by the expert panel to have had inadequate source control in their initial interventions and were therefore not considered evaluable. In addition, 5 patients with a second surgical procedure and an outcome of cure were considered by the panel as clinical failures and were classified as failures for analysis.
A second trial was performed comparing ertapenem with piperacillin/tazobactam and used a similar source control review process [8] . An expert panel comprising 10 surgeons, 2 interventional radiologists, and 1 study investigator reviewed the adequacy of the surgical source control of the initial intervention. The panel reviewed all cases with a clinical response of failure or indeterminate and all cases with a clinical response of cure who underwent a second intervention. In the first step, 3 reviewers assessed the adequacy of each case independently, and if agreement was not reached, the procedure went to full expert panel review for discussion and consensus decision.
Of the 500 randomized patients, 136 (27%) were reviewed by the expert panel (Table 1) . Of the 136 patients reviewed, 39 (18 ertapenem and 21 piperacillin/tazobactam) were considered f Panel reviewed adequacy of source control in the initial interventional procedure for patients who underwent a second procedure and were initially considered clinical cures by the local investigator. The panel could change the clinical response for these patients from success to failure.
to have had inadequate source control and were therefore not evaluable. In addition, 11 (4 ertapenem and 7 piperacillin/tazobactam) patients who had a second surgical procedure and were considered cured initially were classified as failure by the panel.
Tigecycline
A pooled analysis of data from 2 trials was conducted comparing tigecycline with imipenem/cilastatin [9, 10] . A surgical review board comprising investigators and noninvestigators assessed the adequacy of the initial surgical or interventional radiology procedure for patients classified as failures and for patients whose deaths met criteria to be classified as indeterminate. The surgical review board also determined whether there was evidence of failure at the time of a second surgical procedure in patients determined to be cures who had a second surgical intervention performed prior to the test-of-cure (TOC) assessment. The surgical review board was blinded to treatment. The results of the source control review are not available.
Doripenem
Two trials of identical design were conducted comparing doripenem with meropenem [11, 12] . A surgical review panel consisting of 9 surgeons and 2 interventional radiologists assessed the adequacy of the initial surgical or interventional radiology procedure for patients classified as failures and for patients classified as cures who underwent a second procedure. All patients considered for review were identified before the database was unblinded. Approximately 12% of the randomized patients in the 2 trials met the criteria for source control review (Table 1) . Following their blinded review, the panel assessed 6 patients (3 doripenem and 3 meropenem) to be nonevaluable because of inadequate initial infection source control. The panel changed the clinical response in 10 patients (5 doripenem and 5 meropenem) who underwent a second procedure from cure to failure.
DISCUSSION
The source control review process differed across the 8 clinical trials in terms of the basis for referral of individual cases to the adjudication committee for review, composition and number of members of the committee, and approach used for analysis population definitions and efficacy outcome analyses.
Numbers
Across the 8 clinical trials that were reviewed, 4995 patients were assigned randomly to treatment ( Table 1 ). The percentage of randomized patients who were reviewed for adequacy of source control ranged from 8% (ciprofloxacin/metronidazole) to 27% (ertapenem), a difference due to case screening by the principal investigator in the ciprofloxacin/metronidazole and clinafloxacin trials. The percentage of reviewed cases that were determined by the expert panel to have inadequate source control ranged from 5% (doripenem) to 29% (ertapenem), representing approximately 8% of all randomized patients. The percentage of reviewed cases that were reclassified as failures (from cures) by the expert panel ranged from 3% (ertapenem) to 9% (doripenem).
Analysis Issues
The requirements for clinical development of anti-infective drugs have evolved significantly over the past 2 decades [13] . In particular, there are increasing restrictions on entry criteria for patients in well-controlled trials of antibiotics intended for approval in cIAI (Table 2 ). Source control in appendicitis is well understood, and source control issues with appendicitis patients are uncommon [4] . Limits on enrollment of patients with early perforated appendicitis will result in a higher proportion of more severely ill and complex patients. With this complexity comes an increase in variability in patient-specific factors such as chronic, comorbid conditions, and infection-specific factors, including organ site, pathology, and requirement for more complex surgical intervention. These variables create the need for source control review in the event of potential failure.
In previous trials that enrolled fewer severely ill patients, with relatively high cure rates, the variability caused by patient-and infection-specific factors not related to the activity of the antimicrobial under study were of less concern for potentially masking small but real differences between the antibiotic agents. With the evolution of more restrictive eligibility criteria, the confounding of the outcome assessment introduced by the co-intervention (surgical or percutaneous drainage procedure) becomes more of an issue. Because patient-level data from the reviewed trials were not available to us, we were unable to perform a meaningful evaluation of the statistical impact of adjudication on the clinical outcome results. Ensuring adequate interventional control of the source of infection is an important means for reducing potential confounding factors in these trials and provides for a better assessment of the antibiotic effect.
There are some inconsistencies in how the results of the adjudication process are handled in the efficacy analysis in these trials. Ideally, the primary analysis population should be as close as possible to the intent-to-treat population. For this indication, the most appropriate primary analysis population is the microbiologic intent-to-treat (micro-ITT) population, defined as all randomized patients who have baseline bacterial pathogens associated with cIAI identified in blood or abdominal specimen. Secondary analysis populations should include the microbiologically evaluable population, defined as patients in the micro-ITT population who follow important components of the trial (eg, specified treatment duration and completion of study visits).
Source control adjudication should only impact clinical outcomes and not be included in the definition of the analysis populations. Adjudicated failures may be changed to indeterminate, and adjudicated cures with a second procedure for an identified infection or the use of potentially effective nonstudy antibiotics may be changed to failure or indeterminate. The primary analysis should be conducted in the micro-ITT population where indeterminate and missing outcomes are excluded from the analyses (ie, cure/(cure + failure)). Sensitivity analyses where indeterminate and missing outcomes are considered failures are then recommended to better understand the antibiotic effect, assess potential bias introduction from the source control adjudication, and ensure the robustness of the findings.
RECOMMENDATIONS FOR ASSESSMENT OF ADEQUACY OF SOURCE CONTROL (Table 3)
Operative Management
The definition of an adequate surgical procedure is generally agreed on and involves drainage of all fluid collections, closure or resection of any openings into the gastrointestinal tract, and resection of inflamed tissue. The latter aspect of surgical management is controversial, with recent recommendations focused only on the source of infection as opposed to complete peritoneal debridement.
Percutaneous Management
Source control for cIAIs using surgery or percutaneous catheter drainage should achieve the same endpoint. However, the procedures and time courses for these 2 approaches differ considerably. By the end of a surgical operation, source control is typically achieved. In contrast, by the end of a percutaneous catheter drainage procedure, source control has been initiated. The process is a continuum that starts with the first catheter placement procedure, followed by drainage of infected liquid over several days, and is completed upon removal of the last drainage catheter. The definition of successful source control using percutaneous catheter drainage must include a reasonable time limit and, in general, should be achieved within 4 days.
Recommendations for Source Control Review Process
To facilitate source control review, we recommend that checklists be used at the end of the operation or interventional procedure (Table 4) . These checklists generate sufficient information for the reviewers to determine adequacy when supplemented with available operative and radiographic reports. A detailed plan for source control review should be defined prior to the start of the clinical trial. The case report forms should include an intervention record with information necessary for expeditious and accurate source control review. Qualified members for a source control review panel should be identified prior to the start of the trial and involved in the review and finalization of the specific review plan.
A small number of well-trained reviewers may be most efficient. We recommend that the panel consist of a minimum of 3 qualified surgeons to review cases involving operative interventions and 3 qualified interventional radiologists to review cases involving percutaneous interventions. Two reviewers can perform the initial review, with the third reserved to resolve any discordance. A larger panel may be employed to reduce the individual reviewer workload, dependent on trial size. It is important to note that there are different standards of care for cIAI throughout the world. For example, in some regions, drainage of peritonitis following operative management is considered appropriate. Furthermore, outside of North America and Western Europe, percutaneous drainage is uncommonly used to treat cIAI. The panel should be adjusted to allow for more surgeons to review these cases. The local standard must be accepted, and any review group should include surgeons representing the major contributing regions or countries. The independent panel should review all cases judged as clinical failures at TOC, all cures at TOC that underwent a second procedure, and all cures that received a nonstudy systemic antibiotic between randomization and the TOC visit or between TOC and the long-term follow-up visit.
The panel should be provided with the patient's operative/ procedure notes, case report forms, and any radiologic reports. The panel should be blinded with respect to the investigative site, investigator, patient identifiers, and study drug therapy received by the patient. All decisions from the review panel should be documented in the clinical trial database. The possible outcome scenarios are presented in Table 5 .
As a validation procedure for the recommended source control review process, approximately 10%-20% of randomly selected cases not specified above should be reviewed by the panel for adequacy of source control. This information will provide insight as to the accuracy of the review process. In such cases assessed as clinical cures, however, regardless of adequacy of source control, the reviewers should not alter the classification of clinical outcome.
Finally, even with a rigorous process of source control review and adjudication in the trial design, we recommend that the confounding associated with source control intervention be considered in the sample size determination. By controlling for the confounding in the design of the study as well as the determination of outcome, we may have more certainty in the outcome of these complex clinical trials and the effect of the antibiotic therapy. 
